Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ayvakit (avapritinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Blueprint Medicines, CStone Pharma

Drug class:

CSF-1R inhibitor, PDGFR antagonist, mutant c-KIT inhibitor

Related drugs:

PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	avapritinib Resistant: C3 – Early Trials avapritinib Resistant : C3	avapritinib Resistant: C3 – Early Trials avapritinib Resistant : C3
KIT exon 17 mutation	Thymic Carcinoma	KIT exon 17 mutation	Thymic Carcinoma	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3
KIT exon 17 mutation	Mucosal Melanoma	KIT exon 17 mutation	Mucosal Melanoma	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3
KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation	Gastrointestinal Stromal Tumor	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D